About CollPlant Biotechnologies Ltd. - Ordinary Shares (CLGN)
Collplant Biotechnologies Ltd is a biotechnology company focused on developing innovative solutions for tissue regeneration and wound healing. The company harnesses its proprietary recombinant human collagen technology, which is designed to support the body’s natural healing processes. Collplant’s primary applications include products aimed at treating various medical conditions, including skin wounds, surgical recovery, and orthopedic injuries. By leveraging its advanced biotechnological capabilities, Collplant aims to improve patient outcomes and offer alternatives to traditional treatments in the regenerative medicine field. Read More
The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.
CollPlant (CLGN) Q2 2025 results miss analyst estimates, with revenue of $180K far below expectations. Shares fell in pre-market trading on the earnings disappointment.
CLGN stock results show that CollPlant Biotechnologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
